RhumbLine Advisers
EGRX

RhumbLine Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

RhumbLine Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,246
Closed -$40.6K – 4371
2024
Q2 		$40.6K Sell
7,246
-9,920
-58% -$43.2K ﹤0.01% 3735
2024
Q1 		$89.9K Sell
17,166
-175
-1% -$960 ﹤0.01% 3471
2023
Q4 		$90.7K Buy
17,341
+209
+1% +$2.06K ﹤0.01% 3483
2023
Q3 		$270K Sell
17,132
-31
-0.2% -$557 ﹤0.01% 2983
2023
Q2 		$334K Sell
17,163
-14,525
-46% -$345K ﹤0.01% 2948
2023
Q1 		$899K Buy
31,688
+1,561
+5% +$46.3K ﹤0.01% 2171
2022
Q4 		$881K Sell
30,127
-724
-2% -$23K ﹤0.01% 2201
2022
Q3 		$815K Buy
30,851
+69
+0.2% +$2.53K ﹤0.01% 2253
2022
Q2 		$1.37M Sell
30,782
-2,245
-7% -$103K ﹤0.01% 1969
2022
Q1 		$1.64M Buy
33,027
+885
+3% +$42.5K ﹤0.01% 1913
2021
Q4 		$1.64M Sell
32,142
-969
-3% -$50.2K ﹤0.01% 1985
2021
Q3 		$1.85M Sell
33,111
-4,270
-11% -$210K ﹤0.01% 1954
2021
Q2 		$1.6M Buy
37,381
+933
+3% +$38.5K ﹤0.01% 2050
2021
Q1 		$1.52M Buy
36,448
+1,422
+4% +$66K ﹤0.01% 2023
2020
Q4 		$1.63M Buy
35,026
+125
+0.4% +$5.85K ﹤0.01% 1940
2020
Q3 		$1.48M Buy
34,901
+506
+1% +$22.1K ﹤0.01% 1835
2020
Q2 		$1.65M Sell
34,395
-1,010
-3% -$50.4K ﹤0.01% 1836
2020
Q1 		$1.63M Buy
35,405
+1,602
+5% +$80.4K ﹤0.01% 1650
2019
Q4 		$2.03M Buy
33,803
+1,516
+5% +$90.4K ﹤0.01% 1786
2019
Q3 		$1.83M Sell
32,287
-954
-3% -$53.7K ﹤0.01% 1793
2019
Q2 		$1.85M Buy
33,241
+1,261
+4% +$65.8K ﹤0.01% 1788
2019
Q1 		$1.61M Sell
31,980
-2,125
-6% -$94.6K ﹤0.01% 1826
2018
Q4 		$1.37M Buy
34,105
+7,637
+29% +$394K ﹤0.01% 1860
2018
Q3 		$1.83M Buy
26,468
+2,041
+8% +$155K ﹤0.01% 1706
2018
Q2 		$1.85M Buy
24,427
+4,498
+23% +$283K ﹤0.01% 1715
2018
Q1 		$1.05M Buy
19,929
+428
+2% +$24.9K ﹤0.01% 1919
2017
Q4 		$1.04M Buy
19,501
+2,425
+14% +$135K ﹤0.01% 1925
2017
Q3 		$1.02M Buy
17,076
+1,080
+7% +$65.3K ﹤0.01% 1966
2017
Q2 		$1.26M Sell
15,996
-1,092
-6% -$89.3K ﹤0.01% 1829
2017
Q1 		$1.42M Buy
17,088
+4,648
+37% +$346K ﹤0.01% 1746
2016
Q4 		$987K Buy
12,440
+727
+6% +$52.8K ﹤0.01% 1858
2016
Q3 		$820K Buy
11,713
+2,418
+26% +$134K ﹤0.01% 1930
2016
Q2 		$361K Buy
9,295
+297
+3% +$12.4K ﹤0.01% 2408
2016
Q1 		$364K Sell
8,998
-20
-0.2% -$1.27K ﹤0.01% 2424
2015
Q4 		$800K Buy
9,018
+1,095
+14% +$86.5K ﹤0.01% 1946
2015
Q3 		$587K Buy
7,923
+368
+5% +$30.6K ﹤0.01% 2119
2015
Q2 		$611K Buy
+7,555
New +$492K ﹤0.01% 2204

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RhumbLine Advisers's EGRX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 7,246 shares — an estimated $40.6K sold.

RhumbLine Advisers first reported a position in EGRX in Q2 2015 and held it in 37 quarters. The position peaked at $2.03M in Q4 2019. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • RhumbLine Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 7,246 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $40.6K.
  • RhumbLine Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 37 quarters.
  • RhumbLine Advisers's Eagle Pharmaceuticals, Inc. position peaked at $2.03M in Q4 2019.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.